Kim Yuhree, Matsushita Kunihiro, Sang Yingying, Grams Morgan E, Skali Hicham, Shah Amil M, Hoogeveen Ron C, Solomon Scott D, Ballantyne Christie M, Coresh Josef
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Am J Kidney Dis. 2015 Apr;65(4):550-8. doi: 10.1053/j.ajkd.2014.08.021. Epub 2014 Oct 23.
Epidemiologic data for cardiac abnormality predating decreased kidney function are sparse. We investigated the associations of high-sensitivity cardiac troponin T (hs-cTnT) and N-terminal pro-brain natriuretic peptide (NT-proBNP) with end-stage renal disease (ESRD) risk in a community-based cohort.
A prospective cohort study.
SETTING & PARTICIPANTS: 10,749 white and black participants at the fourth visit (1996-1998) of the Atherosclerosis Risk in Communities (ARIC) Study with follow-up through 2010.
hs-cTnT (3, 6, 9, and 14ng/L) and NT-proBNP (41.6, 81.0, 142.5, and 272.5pg/mL) levels were divided into 5 categories at the same percentiles (32th, 57th, 77th, and 91th; corresponding to ordinary thresholds of hs-cTnT), with the lowest category as a reference.
Incident ESRD defined as initiation of dialysis therapy, transplantation, or death due to kidney disease.
Relative risk and risk prediction of ESRD according to hs-cTnT and NT-proBNP levels based on Cox proportional hazards models.
During a median follow-up of 13.1 years, 235 participants developed ESRD (1.8 cases/1,000 person-years). hs-cTnT and NT-proBNP levels were associated with ESRD risk independently of each other and of potential confounders, including kidney function and albuminuria (adjusted HRs for highest category, 4.43 [95% CI, 2.43-8.09] and 2.28 [95% CI, 1.44-3.60], respectively). For hs-cTnT level, the association was significant even at the third category (HR for 6-8ng/L of hs-cTnT, 2.74 [95% CI, 1.54-4.88]). Their associations were largely consistent even among persons without decreased kidney function or history of cardiovascular disease. hs-cTnT and NT-proBNP levels both significantly improved ESRD prediction (C statistic differences of 0.0084 [95% CI, 0.0005-0.0164] and 0.0045 [95% CI, 0.0004-0.0087], respectively, from 0.884 with conventional risk factors).
Relatively small number of ESRD cases and single measurement of hs-cTnT and NT-proBNP.
hs-cTnT and NT-proBNP levels independently predicted ESRD risk in the general population, with more evident results for hs-cTnT. These results suggest the involvement of cardiac abnormality, particularly cardiac injury, in the progression of reduced kidney function and/or may reflect the useful property of hs-cTnT as an end-organ damage marker.
肾功能下降之前心脏异常的流行病学数据较少。我们在一个基于社区的队列中研究了高敏心肌肌钙蛋白T(hs-cTnT)和N末端脑钠肽前体(NT-proBNP)与终末期肾病(ESRD)风险的关联。
一项前瞻性队列研究。
社区动脉粥样硬化风险研究(ARIC研究)第四次随访(1996 - 1998年)时的10749名白人和黑人参与者,随访至2010年。
hs-cTnT(3、6、9和14ng/L)和NT-proBNP(41.6、81.0、142.5和272.5pg/mL)水平按相同百分位数(第32、57、77和91百分位数;对应hs-cTnT的常规阈值)分为5类,以最低类别为参照。
定义为开始透析治疗、移植或因肾病死亡的新发ESRD。
基于Cox比例风险模型,根据hs-cTnT和NT-proBNP水平对ESRD的相对风险和风险预测。
在中位随访13.1年期间,235名参与者发生了ESRD(1.8例/1000人年)。hs-cTnT和NT-proBNP水平相互独立且独立于潜在混杂因素(包括肾功能和蛋白尿)与ESRD风险相关(最高类别调整后的风险比分别为4.43 [95%可信区间,2.43 - 8.09]和2.28 [95%可信区间,1.44 - 3.60])。对于hs-cTnT水平,即使在第三类别时关联也很显著(hs-cTnT为6 - 8ng/L时的风险比为2.74 [95%可信区间,1.54 - 4.88])。即使在没有肾功能下降或心血管疾病病史的人群中,它们的关联也基本一致。hs-cTnT和NT-proBNP水平均显著改善了ESRD预测(与传统风险因素的C统计量差异分别为0.0084 [95%可信区间,0.0005 - 0.0164]和0.0045 [95%可信区间,0.0004 - 0.0087],传统风险因素的C统计量为0.884)。
ESRD病例数量相对较少,且hs-cTnT和NT-proBNP仅进行了单次测量。
hs-cTnT和NT-proBNP水平独立预测了一般人群中的ESRD风险,hs-cTnT的结果更明显。这些结果表明心脏异常,特别是心脏损伤,参与了肾功能下降的进程,和/或可能反映了hs-cTnT作为终末器官损伤标志物的有用特性。